Cai Lay Veterinary Pharmaceutical JSC (HNX:MKV)
18,000
-700 (-3.74%)
At close: Apr 24, 2026
HNX:MKV Revenue
Cai Lay Veterinary Pharmaceutical JSC had revenue of 36.03B VND in the quarter ending March 31, 2026, with 7.82% growth. This brings the company's revenue in the last twelve months to 152.40B, up 31.03% year-over-year. In the year 2025, Cai Lay Veterinary Pharmaceutical JSC had annual revenue of 149.79B with 39.94% growth.
Revenue (ttm)
152.40B
Revenue Growth
+31.03%
P/S Ratio
0.59
Revenue / Employee
1.36B
Employees
112
Market Cap
90.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 149.79B | 42.75B | 39.94% |
| Dec 31, 2024 | 107.04B | -3.87B | -3.49% |
| Dec 31, 2023 | 110.91B | -8.73B | -7.30% |
| Dec 31, 2022 | 119.63B | 17.22B | 16.82% |
| Dec 31, 2019 | 102.41B | -32.17B | -23.90% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vidipha Central Pharmaceutical JSC | 971.25B |
| Ben Tre Pharmaceutical JSC | 860.31B |
| Vimedimex Medi-Pharma JSC | 812.98B |
| Pharmedic Pharmaceutical Medicinal JSC | 546.57B |
| Central Pharmaceutical Joint Stock Company No3 | 481.09B |
| Mediplantex National Pharmaceutical JSC | 366.83B |
| Lamdong Pharmaceutical JSC | 243.91B |
| SPM Corporation | 217.45B |